- Home
- KALV vs VERV Comparison
KALV vs VERV Comparison
Compare KALV & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- VERV
- Stock Information
- Founded
- KALV N/A
- VERV 2018
- Country
- KALV United States
- VERV United States
- Employees
- KALV N/A
- VERV N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- VERV Medicinal Chemicals and Botanical Products
- Sector
- KALV Health Care
- VERV Health Care
- Exchange
- KALV Nasdaq
- VERV Nasdaq
- Market Cap
- KALV 418.1M
- VERV 475.0M
- IPO Year
- KALV N/A
- VERV 2021
- Fundamental
- Price
- KALV $8.36
- VERV $5.74
- Analyst Decision
- KALV Strong Buy
- VERV Strong Buy
- Analyst Count
- KALV 6
- VERV 4
- Target Price
- KALV $26.25
- VERV $25.75
- AVG Volume (30 Days)
- KALV 421.6K
- VERV 1.8M
- Earning Date
- KALV 12-31-2024
- VERV 11-05-2024
- Dividend Yield
- KALV N/A
- VERV N/A
- EPS Growth
- KALV N/A
- VERV N/A
- EPS
- KALV N/A
- VERV N/A
- Revenue
- KALV N/A
- VERV $24,396,000.00
- Revenue This Year
- KALV N/A
- VERV $97.47
- Revenue Next Year
- KALV N/A
- VERV N/A
- P/E Ratio
- KALV N/A
- VERV N/A
- Revenue Growth
- KALV N/A
- VERV 219.91
- 52 Week Low
- KALV $7.98
- VERV $4.31
- 52 Week High
- KALV $16.88
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- KALV 36.75
- VERV 49.30
- Support Level
- KALV $8.48
- VERV $4.88
- Resistance Level
- KALV $9.30
- VERV $7.40
- Average True Range (ATR)
- KALV 0.65
- VERV 0.61
- MACD
- KALV -0.06
- VERV -0.12
- Stochastic Oscillator
- KALV 17.12
- VERV 30.94
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.